In a partnership announced today, MedImmune, AstraZeneca’s global biologics and development arm, and the University of California, San Francisco will initiate further exploration of disease biology, specifically delving into core underlying mechanisms in microbiome and regenerative medicine. With an emphasis on basic research and translational sciences, the organizations’ work will include working toward identifying biomarkers and understanding disease progression and the effects of biomarkers on clinical trial outcomes.
{iframe}http://www.genengnews.com/gen-news-highlights/medimmune-and-ucsf-announce-seven-project-partnership/81252226/{/iframe}